A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.
US Sickle Cell Gene Therapy Contracting Demo Attracting Interest From States
The US Medicaid agency says states representing more than 80% of sickle cell patients are interested in a centralized contracting program, but House Republicans want legislation, not administrative interventions, to shape value-based payment for curative therapies.
